A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
Status:
Recruiting
Trial end date:
2023-03-24
Target enrollment:
Participant gender:
Summary
INV-202-CL-105 is a phase 1B study to examine the safety and tolerability, as well as the
pharmacokinetics (PK) pharmacodynamic (PD) effects of INV-202 in subjects with metabolic
syndrome over 28 days.